Preventing Postpartum Preeclampsia with Low-Dose Aspirin: A Randomized Controlled Trial

Preeclampsia, defined as new or worsening hypertension along with new onset proteinuria and/or end organ damage throughout pregnancy, is one of the leading causes of perinatal and maternal morbidity and mortality. Antepartum preeclampsia has been extensively studied, and prophylaxis with 81mg aspirin starting between 12- and 16-weeks’ gestation is the current standard for prevention. However, little is known about the prevention of new onset postpartum preeclampsia, which can present up to 6 weeks postpartum. In this study, we will evaluate the efficacy of aspirin in preventing the incidence of new onset postpartum preeclampsia. Using a randomized controlled trial, we will determine whether continuing low-dose aspirin use for 6 weeks postpartum is an effective intervention in preventing new onset postpartum preeclampsia in patients with risk factors. These results will provide evidence in favor of a cost-effective treatment regimen that could prevent new onset postpartum preeclampsia and help reduce morbidity and mortality